Photodynamic therapy for conditions of the eye
View Patent ↗The use of a combination of photodynamic therapy and an anti-VEGF agent in the treatment of conditions characterized by unwanted choroidal neovasculature is described. These conditions include wet age-related macular degeneration Preferred anti-VEGF agents are antibodies such as bevacizumab or ranibizumab Photosensitizers may be selected from green porphyrins such as BPD-MA (verteporfin) and the photodynamic activation of the photo sensitizer may be accomplished using a reduced fluence rate. The use may further comprises an anti-inflammatory agent such as dexamethasone.
1. A method for treating unwanted choroidal neovasculature (CNV) in a human subject using photodynamic therapy (PDT), said method comprising:
(a) administering BPD-MA to said subject afflicted with said neovasculature in an amount effective to permit an effective amount to localize in said ocular target tissue, and irradiating said target tissue with electromagnetic radiation containing a wavelength absorbable by said BPD-MA,
(b) administering to said subject an effective amount of ranibizumab,
wherein said administering of said ranibizumab takes place in a shortened time period subsequent to step (a), and wherein closure of CNV in said subject is effected,
wherein said method is further selected from the group consisting of:
i) administering BPD-MA and irradiating at 300 mW/cm 2 for about 83 seconds to deliver 25 J/cm 2 , followed within about two hours by administration of intravitreal ranibizumab;
ii) administering BPD-MA and irradiating at about 300 mW/cm 2 for about 83 seconds to deliver 25 J/cm 2 , followed within about two hours by intravitreal ranibizumab, followed by administration of intravitreal dexamethasone; and
iii) administering BPD-MA and irradiating at 180 mW/cm 2 for about 83 seconds to deliver 15 J/cm 2 followed within about two hours by intravitreal ranibizumab, followed by administration of intravitreal dexamethasone.
2. The method of claim 1 , wherein said CNV is in a subject afflicted with or diagnosed with age-related macular degeneration (AMD).
3. The method of claim 2 , wherein the AMD is the wet form.
4. The method of claim 3 , wherein the AMD is the predominantly classic, minimally classic, or occult form.
5. The method of claim 1 , wherein the PS is administered as a pharmaceutical composition selected from the group consisting of a liposome, emulsion, or aqueous solution.
6. The method of claim 1 , wherein the dexamethasone is delivered intravitreally.
7. The method of claim 6 , wherein said dexamethasone is administered at a dose of between about 0.4 and about 0.8 mg, and within about 2 hours of step (a), and subsequent to administration of said anti-VEGF.
8. The method of claim 1 , wherein the method is repeated for a period of about at least 6 months or more following first treatment.
9. The method of claim 8 , wherein the method is repeated about every three months for a period for about at least 6 months or more following first treatment.
10. The method of claim 9 , wherein the method is repeated no less than about every 55 days for a period of at least 6 months following first treatment.
11. The method of claim 1 , wherein visual acuity in said subject is improved.
12. The method of claim 1 , wherein said method is repeated no less than about every 55 days for a period of about 6 months or more.
13. The method of claim 1 , wherein the method comprises administering BPD-MA and irradiating at 300 mW/cm 2 for about 83 seconds to deliver 25 J/cm 2 , followed within about two hours by intravitreal ranibizumab, followed by administration of intravitreal dexamethasone, and wherein the method is repeated about 3 times over a twelve month period.
14. The method of claim 1 , wherein the method comprises administering BPD-MA and irradiating at 180 mW/cm 2 for about 83 seconds to deliver 15 J/cm 2 followed within about two hours by intravitreal ranibizumab, followed by administration of intravitreal dexamethasone, and wherein the method is repeated about four times over a twelve month period.
15. The method of claim 11 , wherein the visual acuity letter score improvement from baseline after six months is at least about 2.5 letters or more.
16. The method of claim 15 , wherein the visual acuity letter score improvement from baseline after six months is at least about 4 letters or more.
17. The method of claim 16 , wherein the visual acuity letter score improvement from baseline after six months is at least about 7 letters or more.
18. The method of claim 1 where the shortened time period between administration of the PS and subsequent to administration of the anti-VEGF agent comprises about 2 hours.
19. The method of claim 15 , wherein the visual acuity letter score improvement from baseline after six months is at least about 3.6 letters or more.
20. The method of claim 19 , wherein the visual acuity letter score improvement from baseline after six months is at least about 5 letters or more.
21. The method of claim 20 , wherein the visual acuity letter score improvement from baseline after six months is at least about 6.8 letters or more.